Abstract
Recently, the tracer 123I-2-([2-({dimethylamino}methyl)phenyl]thio)-5-iodophenylamine ([ 123I]ADAM) has been developed for selective imaging of serotonin transporters (SERTs) with single photon emission computed tomography (SPECT). The purpose of this study was to develop an [ 123I]ADAM SPECT protocol for clinical studies in young adults. Methods We examined the time course of [ 123I]ADAM binding to central SERTs in eight healthy young volunteers up to 6 h postinjection. Results We found that the time of peak-specific [ 123I]ADAM binding was highly variable among subjects, but specific binding in the SERT-rich (hypo)thalamus peaked within 5 h postinjection in all subjects. Moreover, in this brain area, binding ratios of specific to nonspecific binding did not significantly change between 3 and 6 h postinjection, and peaked 5 h postinjection. Conclusions Five hours postinjection may be optimal for single-scan [ 123I]ADAM SPECT studies in humans, but more work is needed to assess the accuracy of the 5-h tissue ratio as a measure of SERT in the brain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
